Pharmacokinetics of oseltamivir in infants under the age of 1 year

Rashmi Dixit1,2*, Slade Matthews2, Gulam Khandaker1, Karen Walker1,2, Marino Festa1,2 and Robert Booy1,2

Abstract

Background: Oseltamivir is the only antiviral treatment recommended for influenza in young children over the age of 1 year. There is scant data on oseltamivir pharmacokinetics (PK) in infants <1 year. We set out to perform PK measurements in infants who received oseltamivir.

Methods: This study was a prospective, uncontrolled, open label evaluation of the pharmacokinetics of oseltamivir metabolism, safety of oseltamivir, viral clearance in infants <12 months diagnosed with influenza by nasopharyngeal influenza nucleic acid antigen test (NAAT). Blood levels of the prodrug oseltamivir and its active carboxylate were measured prior to a dose of oseltamivir and at 4 time points afterwards, to calculate C_{max} (ng/mL), T_{max} (h), AUC_{0-t} (ng h/mL) and time for AUC (h).

Results: Four children with influenza A received oral oseltamivir, 2.35–3 mg/kg/dose. This dose range produced a target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL, selected from earlier studies to avert resistance. One patient developed GIT adverse event: dry retching.

Conclusion: Oseltamivir was well tolerated at a dose of 2.35–3 mg/kg/dose twice a day in infants under the age of 1 year. In general agreement with earlier data, these doses produced a target oseltamivir carboxylate plasma exposure in excess of the proposed 12-h target exposure of AUC equal to 3800 ng h/mL in two patients. The limited plasma concentration data in the remaining two patients were not inconsistent with the target exposure being reached.

Keywords: Oseltamivir, Infants, Influenza, Paediatrics
infants 9–11 months, based on evidence that these doses achieve an oseltamivir carboxylate 12 h area-under-the-curve (AUC) target of 3800 ng h/mL, and promote less oseltamivir resistance than lower doses [21–24]. The FDA recommends 3 mg/kg BID for infants <1 year of age [25]. During the 2011 influenza season at the Children's Hospital, Westmead (CHW) in Sydney, Australia, pharmacokinetic data was collected from a series of four infants admitted to intensive care and treated with oseltamivir.

**Methods**

**Study population**

Infants aged <12 months who warranted treatment with oseltamivir for influenza-like illness were included. The Sydney Children's Hospitals Network Human Research Ethics Committee provided ethics approval (approval number: HREC/10/CHW/61). All patients or caregivers signed informed consent forms.

**Study design and end points**

This study was a prospective, open label evaluation of the pharmacokinetics of oseltamivir metabolism, safety of oseltamivir, viral clearance. The oseltamivir dose prescribed was at the attending clinician's discretion.

**Pharmacokinetic analysis**

Specific recommendations were made for the timing of blood samples to measure levels of oseltamivir and oseltamivir carboxylate. However, to minimize the number of tests and patient discomfort, samples were collected at the same time as clinically required samples, whenever possible. Recommended times of sample collection were within 15 min prior to an oseltamivir dose, 1 h ± 15 min, 2–3 h, 5–7 h and 10–12 h post dose. The blood volume required for plasma level determination was 500 µL. Blood was collected into a sodium fluoride/EDTA collection tube, placed on ice and centrifuged (1500 g at 4 °C for 10 min). Plasma was stored at −70 to −80 °C before despatch to the laboratory (PRA Early Development Services, Inc. Kansas, USA). Oseltamivir and oseltamivir carboxylate concentrations were determined by high-performance liquid chromatography with tandem mass spectrometric detection [18].

We adopted a desirable target exposure value proposed by Kimberlin of an AUC12 of oseltamivir carboxylate of 3800 ng h/mL [21]. For computational purposes, concentrations at t = −15 min were taken as concentration at zero time. Non-compartmental analysis was conducted using PKSolver, a published pharmacokinetic analysis Excel plugin [26] to obtain estimates of exposure including AUC0−t and Cmax. A set of 5 time-points from zero to 10 h in the 6th dose cycle was available for two of the four patients while for the other two patients only two time-points were available each, for one patient in the 7th dose-cycle and for the other patient in the 8th dose-cycle. It can be assumed that the patients were at steady-state by this time hence the sparsely sampled data may still give an impression of the exposure to oseltamivir carboxylate in these patients.

**Virological analysis**

Each nasopharyngeal swab or aspirate was obtained using a sterile synthetic tip swab, with a plastic or aluminium shaft, and inserted into vials containing sterile viral transport medium. These were collected at treatment initiation and analysed at the Children's Hospital, Westmead; Sydney, Australia. Influenza was diagnosed and strain type determined using nucleic acid amplification testing (NAAT) by polymerase chain reaction (PCR).

**Safety evaluation**

An adverse event was defined as any untoward medical occurrence in a patient which may or may not have a causal relationship with the administered oseltamivir. The following biomarkers were assessed during oseltamivir treatment and compared to pre-treatment levels: serum creatinine, electrolytes, liver transaminases (AST, ALT), alkaline phosphatase, total bilirubin level and full blood count.

**Results**

Four children received oral oseltamivir: three at 3 mg/kg twice a day (bd) and one at 2.35 mg/kg bd. All four patients were infected with influenza A, patients 1–3 were H1N1 and the strain was not documented for the patient 4.

The following table presents the pharmacokinetic parameters for oseltamivir in these four patients (Table 1).

From the AUC0−t estimates, the first two patients (1 and 2) attained oseltamivir carboxylate plasma concentrations in excess of the proposed 12-h target AUC value for antiviral therapy during the 0 to approximately 10-h period; it can be surmised that a 0–12 h AUC exposure value would also be in excess of the proposed therapeutic target given these AUC0−t values (Fig. 1). The two patients with only two samples per dose cycle were exposed to 1747 and 2156 ng h/mL for periods of 2.3 and 6.5 h, respectively. These levels of exposure are not inconsistent with adequate oseltamivir carboxylate exposure sufficient to provide effective therapy given the proposed target AUC12 of 3800 ng h/mL, but further plasma time points would have allowed for confirmation.
Table 1 Patient and pharmacokinetic data for oseltamivir carboxylate in children receiving oral oseltamivir twice a day

| Patient number | Age months (m) and days (d) | Sex | Weight (kg) | Dose (mg/kg/dose) | Dose cycle | C<sub>max</sub> (ng/mL) | T<sub>max</sub> (h) | AUC<sub>0–t</sub> (ng h/mL) | Time for AUC (h) | No. plasma samples |
|---------------|----------------------------|-----|-------------|-------------------|------------|------------------------|----------------|--------------------------|----------------|------------------|
| 1             | 6 m, 23 d                  | F   | 905         | 3                 | 6          | 772                    | 9.4           | 6376                     | 0–9.4         | 5                |
| 2             | 5 m, 13 d                  | F   | 930         | 3                 | 6          | 1960                   | 5.8           | 18,816                   | 0–10          | 5                |
| 3             | 11 m, 15 d                 | F   | 5.69        | 3                 | 7          | 443                    | 3.7           | 1747                     | 3.7–6         | 2                |
| 4             | 3 m, 13 d                  | M   | 6.43        | 2.35              | 8          | 466                    | 11.5          | 2156                     | 5–11.5        | 2                |
All patients recovered from acute influenza during their intensive care unit admissions. One infant suffered an adverse event: self-limited dry retching (Table 2).

Discussion

Our results are consistent with the proposition that a dose of 2.35–3 mg/kg produced a target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL.

Oseltamivir is well absorbed from an early age. Animal studies demonstrate a rapid increase of the transport protein at birth, and a widespread distribution for oseltamivir including good penetration of lung tissue, the middle ear and the nasal mucosa [27]. It is metabolized to the active metabolite oseltamivir carboxylate by the liver carboxylesterase HCE1 [19, 27]. Production of HCE1 is lower in foetuses than in infants <1 year of age, who in turn have lower gene transcription than children 1–10 years [18]. However, much inter-individual variability exists, particularly in the younger age groups. Young children have greater proportionate extracellular fluid and thus a greater volume of distribution (VD) of oseltamivir carboxylate, resulting in a lower circulating plasma concentration compared to older children and adults [27]. Oseltamivir carboxylate is not extensively protein bound and, thus, immaturity of plasma protein levels does not impact on VD [27]. Animal studies indicate good penetration of oseltamivir carboxylate into respiratory tissues [19]. Oseltamivir has been linked to neuropsychiatric side effects in children and young adults, especially in Japan, although it is unclear whether the encephalopathy was induced by influenza or by its treatment [28, 29]. Both rat and human foetus studies showed certain central nervous system (CNS) efflux pumps to be in low numbers at birth and increase with age, whilst others are present from the second trimester [19]. There was, however, no accumulation of oseltamivir carboxylate in the brains of healthy rats. Oseltamivir is filtered and actively excreted from the renal tubules using OAT transporter proteins [27]. Clearance function of these proteins is low at birth and increases over the first year of life, which may lead to reduced oseltamivir clearance in neonates [27]. Oo et al. demonstrated that oseltamivir carboxylate clearance adjusted for body surface area (BSA) reached adult levels by 6–9 months of age, whilst a higher BSA-to weight ratio in those 1–2 years resulted in higher clearance and consequently lower peak plasma concentration (C_{max}), time to reach C_{max} (T_{max}) and AUC compared to those 3–5 years.

Table 2  Adverse events (AE) in children receiving oral oseltamivir

| Patient number | Age months (m) and days (d) | Comorbidities | Clinical AE | Laboratory changes |
|----------------|-----------------------------|---------------|-------------|-------------------|
| 1              | 6 m, 23 d                   | Tetralogy of Fallot | D1          | Day 1 bloods: raised creatinine (48 mmol/L) and AST (66 mmol/L) Attributed to cardiac condition Normalised after frusemide dose during course of oseltamivir |
|                |                             |                | Dry-retching | Nil               |
| 2              | 5 m, 13 d                   | Albright's osteodystrophe Hypothyroidism Hyperparathyroidism GORD Severe OSA due to epiglottis dystrophy | Nil | Nil |
| 3              | 11 m, 15 d                  | Streptococcus pneumoniae bacteremia, pneumonia, meningitis Parainfluenza 3/rhinovirus/enterovirus co-infection Developed HUS | Nil | Baseline bloods normal D2 of oseltamivir: rising creatinine, urea, AST/ALT/GGT All parameters normalised 10 days after first dose Laboratory abnormalities attributed to HUS |
| 4              | 3 m, 13 d                   | Exomphalmhos | Nil | Nil |

GORD gastro-oesophageal reflux disease, OSA obstructive sleep apnoea, HUS haemolytic uraemic syndrome
Conclusion

Oseltamivir was well tolerated at a dose of 2.35–3 mg/kg/dose twice a day in infants under the age of 1 year. These doses were confirmed to produce a target oseltamivir carboxylate plasma exposure in excess of the proposed 12-h target exposure of AUC 3800 ng h/mL in two patients and the limited plasma concentration data in the remaining two patients were not inconsistent with the target exposure being reached.

Authors’ contributions

RD, GK, and RB contributed to the design of the study. RD, MF, GK and KW contributed to data acquisition. RD and SM performed pharmacokinetic analysis and data interpretation. RD, GB, RB and SM all contributed to writing of final manuscript. All authors read and approved the final manuscript.

Author details

1 The Children’s Hospital, Westmead, Sydney, Australia. 2 The University of Sydney, Sydney, Australia.

Acknowledgements

The authors wish to acknowledge the participants and their families for their generous support.

Competing interests

The authors declare that they have no competing interests. Authors Booy and Khandaker have worked on unrelated projects funded by Roche in the past but have not received any form of remuneration or in kind support from the company. Author Festa has received funding for Intensive Care Unit (ICU) equipment unrelated to this study.

Received: 10 March 2016 Accepted: 15 August 2016 Published online: 05 September 2016

References

1. Munoz FM (2002) The impact of influenza in children. Semin Pediatr Infect Dis 13:72–78
2. Milne BG, Williams S, May MLA et al (2004) Influenza A associated morbidity and mortality in a Paediatric Intensive Care Unit. Commun Dis Intell 28:504–509
3. The ANZIC Influenza Investigators (2009) Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 361:1925–1934
4. Fiore AE, Fry A, Shay D et al (2011) Antiviral agents for the treatment and prophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60:1–24
5. Communicable Diseases Network Australia. Influenza infection CDNA National Guidelines for Public Health Units. Series of national guidelines. 2011
6. Health Protection Services (2012) HPA guidance on use of antiviral agents for the treatment and prophylaxis of influenza. Version 3. Health Protection Agency
7. Barakatfleitio A and Noble S (1999) Oseltamivir. Drugs 58:851–860, discussion 861–852
8. Whitley RJ, Hayden FG, Reisinger KS et al (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133
9. Heinonen S, Silvennoinen H, Lehtinen P et al (2010) Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis 51:887–894
10. Goodell R (2012) Open letter to Roche about oseltamivir trial data. BMJ 345:e7305
11. Jefferson T et al (2009) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339:b1056
12. Buck ML(2012) An update on oseltamivir use in infants and children. Pediatr Pharm 18(9)
13. U.S. Food and Drug Administration (2012) FDA expands Tamifl’s use to treat children younger than 1 year. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm
14. Kimberlin DW, Shalabi M, Abzug MJ et al (2010) Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 29:195–198
15. Okamoto S, Kamiya I, Kishida K et al (2005) Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 24:575–576
16. Siedler K, Skopnik H (2010) Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 29:495–498
17. Tamura D, Miura T, Kikuchi Y (2005) Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int 47:484
18. Yang D, Pearce RE, Wang X et al (2009) Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 77:238–247
19. Abdel-Rahman SM, Newland JG, Kearns GL (2011) Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr Drugs 13:19–31
20. Oo C, Hill G, Dorr A, Luu B, Boelner S, Ward P (2003) Pharmacokinetics of anti-influenza produg oseltamivir in children aged 1–5 years. Eur J Clin Pharmacol 595–6:411–415 (Epub 2003 Aug 9)
21. Kimberlin DW, Acosta EP, Prichard NN et al (2013) Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis 207(5):709–720
22. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowsk R, Ward P, Carr J (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189(3):440–449 (Epub 2004 Jan 26)
23. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowsk R, Ipe D, Mills RG, Ward P (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20(2):127–133
24. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraiishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoaka Y (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436):759–765
25. US (2012) Food and Drug Administration. FDA expands Tamiflu’s use to treat children younger than 1 year. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm
26. Zhang Y, Huo M, Zhou J, Xie S (2010) PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 99(3):306–314
27. He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prod- rug oseltamivir and its active metabolite Ro 64–0802. Clin Pharmacokin 37:471–484
28. Maxwell SR (2007) Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334:1232–1233
29. Dalvi PS, Singh A, Trivedi HR, Mistry SD, Vyas BR (2011) Adverse drug reaction profile of oseltamivir in children. J Pharmacol Pharmacother. 2(2):100–103
30. Pannaraj PS, Tam B, Akan D (2011) Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol 31(7):487–493. doi:10.1038/jp.2010.159 (Epub 2011 Jan 13)
31. Kara A, Karadağ-Oncel E, Ozkaya-Parlakay A, Korukluoğlu G, Bağdát A, Celik M, Ceyhan M, Cengiz AB (2012) Oseltamivir use in infants under one year of age: are there still unanswered questions? Turk J Pediatr 54(1):25–29
32. Holgate Sandi L, Bekker Adrie, Rabie Helena, Cotton Mark F (2012) Oseltamivir use in low-birth weight infants during the 2009 nH1N1 influenza A outbreak in the Western Cape. South Africa. J Trop Pediatr 58(2):102–106